Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Syrian Refugees Crisis Impact on Lebanese Public Hospitals- Financial Impact Analysis: APIS Report


The impact of the Syrian crisis on Lebanon has been profound particularly in the healthcare sector. The influx of Syrian refugees has strained the public hospitals and their ability to respond to the crisis, resulting in:
  • An increased demand for healthcare services;
  • An increase in unpaid health services to refugees;
  • A sharp rise in communicable diseases and emergence of new diseases in Lebanon;
  • Increased risks of epidemics such as water-borne diseases, measles, and tuberculosis 1.
Neither United Nations High Commissioner of Refugees (UNHCR) nor other Non-Governmental Organizations (NGO) was able to meet the required level of funding to provide refugees with an acceptable level of secondary and tertiary healthcare services. They, therefore, decided to change their model of response in terms of healthcare support to Syrian refugees. As of 2014, UNHCR started covering 75% instead 85% of the hospitalization cost, leaving the patient with the remaining share of 25% to be paid out of pocket or by a third party. The healthcare referrals covered by UNHCR are limited to deliveries and life-threatening emergencies 2.

Hospitals are overburdened with Syrian patients who are unable to pay their part of the bill (increased to 25% of their total hospital fees) as well as patients whose hospitalizations are not subsidized at all. Some hospitals have put in place strategies to recover as much of the 25% as possible (deposits, retaining IDs/corpses, inflating bills). Referral of uncovered Syrian patients with complicated morbidities to public hospitals has become a common practice by private hospitals.

Overwhelmed by the high demand of healthcare by Syrian refugees, public hospitals end up treating patients without any specific reimbursement scheme thus creating a huge financial burden. This burden adds up to the existing difficult financial situation of public hospitals, putting the whole healthcare sector under stress. Public hospitals are restrained from completing their mission and incapable of providing healthcare services neither to Syrians refugees nor to Lebanese citizens...
    3
ATC Name B/G Ingredients Dosage Form Price
A10BA02 GLUFORIN XR 1000 G Metformin HCl - 1000mg 1,000mg Tablet, film coated, extended release 579,772 L.L
A10BA02 GLUFORIN XR 500 G Metformin HCl - 500mg 500mg Tablet, film coated, extended release 349,399 L.L
L01BC05 GEMCITABIN EBEWE G Gemcitabine (HCl) - 200mg/20ml 200mg/20ml Injectable concentrated solution 2,121,927 L.L
A10BB01 GLIBENCLAMIDE G Glibenclamide - 5mg 5mg Tablet, scored 340,440 L.L
L01BC05 GEMCITABINE NEAPOLIS G Gemcitabine (HCl) - 200mg 200mg Injectable powder for solution 1,490,321 L.L
A10BB01 GLIBENCLAMIDE G Glibenclamide - 5mg 5mg Tablet 326,362 L.L
L01BC05 GEMCITABINE THYMOORGAN G Gemcitabine (HCl) - 200mg 200mg Injectable powder for solution 1,617,986 L.L
M02AA15 GROFENAC G Diclofenac sodium - 1% Emulsion Gel 314,459 L.L
A10BB09 GLYZIDE G Gliclazide - 80mg 80mg Tablet 534,849 L.L
L01BC05 GEMNIL G Gemcitabine (HCl) - 200mg 200mg Injectable powder for solution 1,128,828 L.L
L01BC05 GEMTABINE 200 G Gemcitabine HCl - 200mg 200mg Injectable lyophilised powder for solution 1,343,843 L.L
L01BC05 GEMCI-CELL G Gemcitabine (HCl) - 1g/Vial 1g/Vial Injectable concentrate for solution 9,326,123 L.L
L01BC05 GEMCITABIN EBEWE G Gemcitabine (HCl) - 1g/100ml 1g/100ml Injectable concentrated solution 7,512,674 L.L
L01BC05 GEMCITABINE NEAPOLIS G Gemcitabine (HCl) - 1000mg 1000mg Injectable powder for solution 4,942,653 L.L
A10BB12 GLIM G Glimepiride - 1mg 1mg Tablet 302,365 L.L
L01BC05 GEMCITABINE THYMOORGAN G Gemcitabine (HCl) - 1g 1g Injectable powder for solution 5,843,027 L.L
A10BB12 GLUMYL 1 G Glimepiride - 1mg 1mg Tablet 186,858 L.L
G02AX GYNOCIN G Oxytocin - 10IU/ml 10IU/ml Injectable concentrate for solution 626,231 L.L
L01BC05 GEMNIL G Gemcitabine (HCl) - 1g 1g Injectable powder for solution 3,369,013 L.L
L01BC05 GEMTABINE 1000 G Gemcitabine HCl - 1,000mg 1,000mg Injectable lyophilised powder for solution 4,882,628 L.L
D01BA01 GRISEOFULVIN G Griseofulvin - 500mg 500mg Tablet, scored 575,933 L.L
G02AX GYNOCIN G Oxytocin - 5IU/0.5ml 5IU/0.5ml Injectable concentrate for solution 313,115 L.L
A10BB12 GLIM G Glimepiride - 2mg 2mg Tablet 401,809 L.L
A10BB12 GLUMYL 2 G Glimepiride - 2mg 2mg Tablet 189,418 L.L
A10BB12 GLYPRIDE G Glimepiride - 2mg 2mg Tablet 403,153 L.L
A10BB12 GLIM G Glimepiride - 3mg 3mg Tablet 533,505 L.L
A10BB12 GLUMYL 3 G Glimepiride - 3mg 3mg Tablet 511,940 L.L
A10BB12 GLYPRIDE G Glimepiride - 3mg 3mg Tablet 571,133 L.L
N02BE51 GENTLE RELIEF G Paracetamol - 325mg, Ibuprofen - 400mg, Famotidine - 20mg Tablet 184,106 L.L
D02AX GLYCERINE G Glycerol - Liquid 163,821 L.L
    3
Sitemap
© Copyrights reserved to Ministry of Public Health 2025